

# WE'LL KEEP THE DOSE ON

**Dextenza**<sup>®</sup>  
(dexamethasone ophthalmic insert) 0.4 mg  
for intracanalicular use

**DELIVERING SUSTAINED STEROID COVERAGE,  
FOR A HANDS-FREE POST-OP EXPERIENCE.**<sup>1,2</sup>

**DEXTENZA is designed to:**

- Allow for physician-controlled administration<sup>1</sup>
- Provide preservative-free, sustained coverage for up to 30 days<sup>2</sup>

## INDICATION

DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

### WARNINGS AND PRECAUTIONS

Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

### ADVERSE REACTIONS

The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

**References:** 1. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013.  
2. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc. 2019.

© 2020 Ocular Therapeutix, Inc. All rights reserved.  
DEXTENZA is a registered trademark of Ocular Therapeutix, Inc. PP-US-DX-0262

**Ocular**  
Therapeutix<sup>™</sup>

# ONBOARD AND **UNDER YOUR CONTROL**

## DEXTENZA is an advancement in steroid treatment

- Resorbable, so no need for removal<sup>1</sup>
  - Insert can be removed via saline irrigation or manual expression, if necessary<sup>1</sup>
- Physicians rated DEXTENZA as easy to insert<sup>2,3\*</sup>
- Designed to deliver a tapered dose<sup>4</sup>
- Contains fluorescein for visualization<sup>1</sup>
- No additional components or assembly required<sup>1</sup>

\*73.6% of physicians in Study 1, 76.4% in Study 2, and 79.6% in Study 3 rated DEXTENZA as easy to insert.

Over the course of 30 days post-op...


Built-in  
compliance  
with

**1**  
INNOVATIVE  
INSERT<sup>1</sup>

vs


**~70**  
STEROID DROPS<sup>5</sup>

DEXTENZA is dexamethasone delivered via hydrogel technology for a hands-free post-op experience.<sup>1,2</sup>




### Activates<sup>1,2</sup>

With moisture and swells to fit securely in the canaliculus



### Releases<sup>1,2</sup>

Dexamethasone for up to 30 days



### Resorbs<sup>1,2</sup>

Slowly through the course of treatment and clears via the nasolacral duct

## IMPORTANT SAFETY INFORMATION

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

**References:** **1.** Walters T et al. *J Clin Exp Ophthalmol*. 2016;7(4):1-11. **2.** DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix Inc; 2019. **3.** Tyson SL et al. *J Cataract Refract Surg*. 2019;45(2):204-212. **4.** Data on file 00823. Ocular Therapeutix Inc.

Please see Important Safety Information on reverse and full Prescribing Information enclosed.

